Orion Corporation has announced favorable pharmacokinetic study results with combined salmeterol-fluticasone formulation of the Easyhaler product family, developed for the treatment of asthma and COPD. Based on the results Orion is planning to apply for a marketing authorisation for the product in Europe. Orion currently estimates that the marketing authorisation application could be submitted in Europe during the first half of 2017. Orion has developed a salmeterol-fluticasone formulation combining fluticasone as an anti-inflammatory agent and salmeterol as a long-acting bronchodilator to expand the range of the inhalable Easyhaler drug product family for treatment of asthma and COPD. Orion's Easyhaler is an in-house developed dry-powder inhaler. Orion has developed Easyhaler-adapted dry powder formulations of several well-known generic active substances (salbutamol, beclometasone, budesonide, formoterol) used in the treatment of asthma and COPD. The latest product that has been granted marketing authorisation is combined budesonide-formoterol formulation that has been launched in several European countries.